Dagens aktienyheder med Vestjysk Bank, WindowMaster og Gubra

Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 7 November at 12.00 AM when they present the Q3 report 2024. Focus will be on Q3 report and the underlying growth in the CRO business area. Besides that, we expect an update on potential triggers in the D&P pipeline.

Dagens aktienyheder med TORM, Gubra, Asetek, Ascelia Pharma, WindowMaster og Columbus

Today, Gubra reported its Q3 2024 results. The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry.Read more here.

Dagens aktienyheder med Føroya Banki, Gubra, GomSpace og Aktier med Friis

Boehringer Ingelheim, Gubra's partner in multiple obesity projects, has decided to discontinue the clinical obesity project NYP2.

Dagens aktienyheder med Curasight, Gubra, Skjern Bank og bankerne generelt

Dagens aktienyheder med Netcompany, Life Sciences selskaber og Aktier med Friis

Dagens aktienyheder med Columbus, Gabriel, Flügger og Gubra

Hvem er Gubra og hvordan vurderer HCA Capital de enkelte forretningsområder.

Dagens aktienyheder med Gubra og MapsPeople

Dagens aktienyheder med Boozt og Gubra

We have revised our DCF-model, guided by the company, to reflect new estimates for the total obesity market in 2030. With the current share price in line with our latest one-pager from June 2024, the model indicates a lower probability og success (PoS) in the base case.